Trial · NCT00995007
Adverse events651
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 651
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Activated partial thromboplastin time prolonged | Investigations | Carboplatin | 2 | 56 | 2 |
| other | Activated partial thromboplastin time prolonged | Investigations | Vandetanib With Carboplatin | 5 | 56 | 11 |
| other | Activated partial thromboplastin time prolonged | Investigations | Crossover to Vandetanib | 1 | 42 | 1 |
| other | Alanine aminotransferase increased | Investigations | Carboplatin | 19 | 56 | 29 |
| other | Alanine aminotransferase increased | Investigations | Vandetanib With Carboplatin | 43 | 56 | 74 |
| other | Alanine aminotransferase increased | Investigations | Crossover to Vandetanib | 24 | 42 | 29 |
| other | Alkaline phosphatase increased | Investigations | Carboplatin | 4 | 56 | 4 |
| other | Alkaline phosphatase increased | Investigations | Vandetanib With Carboplatin | 17 | 56 | 20 |
| other | Alkaline phosphatase increased | Investigations | Crossover to Vandetanib | 6 | 42 | 6 |
| other | Anemia | Blood and lymphatic system disorders | Carboplatin | 30 | 56 | 67 |
| other | Anemia | Blood and lymphatic system disorders | Vandetanib With Carboplatin | 26 | 56 | 74 |
| other | Anemia | Blood and lymphatic system disorders | Crossover to Vandetanib | 4 | 42 | 4 |
| other | Aspartate aminotransferase increased | Investigations | Carboplatin | 3 | 56 | 3 |
| other | Aspartate aminotransferase increased | Investigations | Vandetanib With Carboplatin | 28 | 56 | 44 |
| other | Aspartate aminotransferase increased | Investigations | Crossover to Vandetanib | 14 | 42 | 17 |
| other | Blood bilirubin increased | Investigations | Carboplatin | 2 | 56 | 2 |
| other | Blood bilirubin increased | Investigations | Vandetanib With Carboplatin | 8 | 56 | 11 |
| other | Blood bilirubin increased | Investigations | Crossover to Vandetanib | 3 | 42 | 3 |
| other | Cardiac disorders - Other, specify (Qtc prolonged) | Cardiac disorders | Carboplatin | 1 | 56 | 1 |
| other | Cardiac disorders - Other, specify (Qtc prolonged) | Cardiac disorders | Vandetanib With Carboplatin | 0 | 56 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00995007/events